Free Republic

Liver fibrosis is a major global health concern, developing as a result of chronic liver diseases (CLDs). Current treatment options are largely supportive, with no widely available therapies that directly target fibrosis. Research suggests that metabolic imbalances, particularly in glycolysis—the process by which cells generate energy—play a key role in disease progression. Identifying treatments that can disrupt these pathways may offer new therapeutic strategies. One emerging approach involves targeting liver sinusoidal endothelial cell (LSEC) glycolysis, which has been linked to inflammation and fibrosis. Quercetin, a naturally occurring flavonoid found in many fruits and vegetables, has attracted attention for its anti-inflammatory...

Having HIV almost doubles the risk of liver fibrosis, according to European research published in the online edition of the Journal of Infectious Diseases. Investigators in Denmark and the Netherlands compared rates of liver fibrosis between people living with HIV and people without HIV. Importantly, none of the participants had hepatitis B virus (HBV) or hepatitis C virus (HCV). All were aged between 50 and 70 years and liver fibrosis was present in 12% of people with HIV and 7% of HIV-negative comparison group. Risk factors for fibrosis among people with HIV included increasing age, higher body mass index (BMI),...